Clinical review report : (Ipsen Biopharmaceuticals Canada, Inc.). AbobotulinumtoxinA (Dysport therapeutic) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (17 pages) : illustrations

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated for the symptomatic treatment of focal spasticity affecting the upper limbs in adults (upper limb spasticity, ULS), and is available in single-use vials of 300 Units (U) and 500 U, at submitted prices of 28.40 and 14.00, respectively. The recommended initial dose of aboBoNTA is individually tailored depending on the size, number, and location of muscles involved. In the pivotal trial, 500 U or 1,000 U were used intramuscularly, divided among selected muscles, at a given treatment session. Repeat treatment should be administered when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection, with a majority of study patients being re-treated between 12 and 16 weeks. The manufacturer is requesting that aboBoNTA be reimbursed for the treatment of adults with focal spasticity, including spasticity of the upper limbs. CADTH Common Drug Review (CDR) previously reviewed aboBoNTA for the treatment of cervical dystonia; CADTH Canadian Drug Expert Committee recommended aboBoNTA be reimbursed in a manner similar to other botulinum neurotoxin A (BoNTA) therapies, and with a price reduction.

Notes:

Description based on publisher supplied metadata and other sources.